Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 3/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.47 |
| ▸ | GSK3B | P49841 | 5/20 | 0.47 |
| ▸ | WNT1 | P04628 | 4/20 | 0.47 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | RHOC | P08134 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17491506 | 0.99 | RHOA (0.60) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17491529 | 0.98 | RHOA (0.58) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17491438 | 0.95 | RHOA (0.55) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17491522 | 0.92 | DYRK1A (0.53) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17491442 | 0.89 | RHOA (0.51) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17491474 | 0.87 | RHOA (0.50) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17491483 | 0.83 | RHOA (0.46) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17506981 | 0.82 | AAK1 (0.52) | RHOADYRK1AGSK3BWNT1CLK2 | |
| SCHEMBL17491399 | 0.81 | RHOA (0.47) | RHOADYRK1AGSK3BWNT1MEN1 | |
| SCHEMBL17491415 | 0.81 | BRAF (0.47) | RHOALMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2982670-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-9624184-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-25 | — | — | US | disclosed |
| EP-2982670-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052897-A1 | HETEROCYCLIC COMPOUND | PSEN1, PSEN2, BACE1 | RHOA 2405/4885DYRK1A 4878/4885GSK3B 2149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.